Table 1

Characteristics of patients with ES-SCLC in included trials

Study name, yearPhaseNo. of total patientsIntervention armNo. of patientsControl armNo. of patientsBaseline BM, No, (%)ORR (%)mPFSHR for PFSmOSHR for OSTumor assessment criteriaNCI CTCAEMedian follow-up time (months)
(months)(95% CI)(months)(95% CI)
Reck et al, 201213 2130Phased Ipi/concurrent Ipi+PC42/43PC45NR*57 vs 33 vs 49*5.2 vs 3.9 vs 5.20.93 (0.59 to 1.45) 0.93 (0.59 to 1.48)12.1 vs 9.1 vs 9.90.75 (0.46 to 1.23) 0.95 (0.59 to 1.54)mWHO/irRC3.011.1
Reck et al, 201614 3954Ipil+EP478EP47655 (12) vs 45 (10)62 vs 624.6 vs 4.40.85 (0.75 to 0.97)11.0 vs 10.90.94 (0.81 to 1.09)mWHO3.010.5
IMpower133, 20189 3403Atezo+EC201EC20217 (8.5) vs 18 (8.9)60.2 vs 64.45.2 vs 4.30.77 (0.62 to 0.96)12.3 vs 10.30.70 (0.54 to 0.91)RECIST V.1.14.013.9
CASPIAN, 2019, 202010 15 3805D+EP/D+T+EP268/268EP26928 (10.4) vs 38 (14.2) vs 27 (10.0)67.9 vs 58.4 vs 58.05.1 vs 4.9 vs 5.40.80 (0.66 to 0.96)12.9 vs 10.4 vs 10.50.75 (0.62 to 0.91)RECIST V.1.14.0325.1
KEYNOTE-60 4 to 202011 3453Pem+EP228EP22533 (14.5) vs 22 (9.8)70.6 vs 61.84.5 vs 4.30.75 (0.61 to 0.91)10.8 vs 9.70.78 (0.63 to 0.97)RECIST V.1.14.021.6
EA5161, 202012 2160Nivo +EP80EP80NR52.0 vs 47.05.5 vs 4.70.65 (0.46 to 0.91)11.3 vs 8.50.67 (0.46 to 0.98)RECIST V.1.15.0NR
  • *According to mWHO criteria.

  • ES-SCLC, extensive-stage small cell lung cancer; BM, brain metastases; ORR, objective response rate; mPFS, median progression-free survival; mOS, median overall survival; NCI CTCAE, National Cancer Institute common terminology criteria for adverse events; Ipi, ipilimumab; Atezo, atezolizumab; D, durvalumab; T, tremelimumab; Pem, pembrolizumab; Nivo, nivolumab; EC, carboplatin and etoposide; EP, cisplatin/carboplatin and deoposide; PC, paclitaxel and carboplatin; NR, not reported; No, numbers; mWHO, modified WHO criteria; irRC, immune-related response criteria; RECIST, Response Evaluation Criteria in Solid Tumors.